Developer docs
API playgroundTry for free, no card

Search company profiles

Rapid Micro Biosystems

Full company profile

uuid0000xyw

Namestring
Rapid Micro Biosystems
Legal namestring
Rapid Micro Biosystems, Inc.
Company typeenum
Public
Founded yearint
2006
Descriptiontext

Rapid Micro Biosystems (Nasdaq: RPID) is a Lexington, Massachusetts-based life sciences technology company that develops and sells the Growth Direct System, an automated rapid microbial detection platform for quality control microbiology in pharmaceutical and biotechnology manufacturing. The system combines LED-induced autofluorescence imaging with proprietary software algorithms to incubate, image, and count microbial colonies non-destructively, replacing manual plate-handling workflows for environmental monitoring, water testing, bioburden testing, and rapid sterility testing. Proprietary consumables — including media cassettes for TSA, R2A, and SDA formulations produced in cleanroom environments in Lowell, MA — generate recurring revenue tied to the installed base, while the RMBNucleus software platform (with Mold Alarm feature) provides instrument management, compliance reporting under 21 CFR Part 11, and bidirectional LIMS/MES integration.

The company operates a hybrid razor-and-blade business model: capital equipment placements of the Growth Direct system, complemented by high-margin recurring consumables, software subscriptions, and validation/support services. Sales are driven by an enterprise field-sales motion targeting pharmaceutical, biologics, sterile injectable, ATMP, and medical-device manufacturers, augmented by a strategic co-distribution partnership with MilliporeSigma (Merck KGaA) that entered its second year with a Q1 2026 Services Agreement. As of year-end 2025, the platform is used by 75% of the top 20 global pharmaceutical companies including Amgen, Biogen, Lonza, and Samsung Biologics.

FY2025 revenue was approximately $34M (up ~20% YoY), with Q4 2025 setting a record at $11.3M (+37% YoY) driven by a 16-system global rollout with Amgen. FY2026 guidance is $37-41M on expected 30-38 system placements. The company raised $45M in growth capital from Trinity Capital in September 2025 and completed an additional ~$9.8M underwritten offering in May 2026 (with up to ~$32M potential if warrants exercise), anchored by Bain Capital Life Sciences and Armistice Capital. Gross margins have lagged (trailing twelve months around 3%) due to under-absorbed manufacturing, but management is targeting mid-20% gross margins by year-end 2026 as production scales.

Short descriptiontext

Rapid Micro Biosystems (Nasdaq: RPID) sells the Growth Direct automated rapid microbial detection platform and proprietary consumables to pharmaceutical and biotechnology manufacturers, replacing manual QC microbiology in environmental monitoring, bioburden, water, and sterility testing. The platform serves 75% of the top 20 global pharma companies and generates revenue from system placements plus recurring consumables and software.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
automated microbial detection, pharmaceutical quality control, rapid sterility testing, environmental monitoring systems, bioburden testing instruments
Industry1 code
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Automated Microbial Quality Control Instrumentation
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Capital Equipment Sales
TypeHardware Sales
Description

Sale of Growth Direct systems (capital equipment) to pharmaceutical and biotechnology manufacturers for automated microbial quality control testing. The company places systems through direct enterprise sales and strategic partnerships.

ad-hoc-news.de
2Consumables and Test Kits
TypeSubscription Recurring
Description

Recurring revenue from proprietary test consumables including environmental monitoring cassettes, bioburden cassettes, and sterility testing media. Stifel noted consumables growth exceeding 30% driven by expansion of the installed base.

ad-hoc-news.de
3Software and Services
TypeSubscription Recurring
Description

Recurring revenue from software licensing (RMBNucleus platform), support services, validation services, and application services. The company announced plans for cloud-native software platform launch in H2 2026.

investing.com
4Validation and Support Services
TypeProfessional Services
Description

Professional services including installation qualification, operational qualification, performance qualification, method qualification, and training. These services support customer implementation and ongoing system maintenance.

rapidmicrobio.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Growth Direct®
Description

Flagship automated rapid microbial detection platform for pharmaceutical QC microbiology testing including environmental monitoring, water testing, bioburden testing, and sterility testing.

rapidmicrobio.com
+2 more records
Core offering1 text field

Rapid Micro Biosystems manufactures and sells the Growth Direct System, an automated rapid microbial detection platform that replaces slow, manual compendial quality control microbiology testing in pharmaceutical and biotechnology manufacturing. The platform combines proprietary autofluorescence imaging hardware, robotic plate handling, RMBNucleus data-management software, and single-use media cassettes to perform environmental monitoring, water testing, bioburden testing, and rapid sterility testing. Revenue is generated from capital equipment sales, recurring consumable cassettes, software licensing, and validation/support services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Time savings of up to 60% in bioburden detection (Biogen case study)
+7 more records
Product overview1 text field

Rapid Micro Biosystems offers a unified platform architecture centered on the Growth Direct System, an automated rapid microbial detection platform that replaces slow, error-prone manual QC microbiology processes. The product portfolio includes the Growth Direct System hardware and software ecosystem, comprising RMBNucleus software (including the Mold Alarm feature) for instrument control, data management, and automated alerts. The platform is complemented by proprietary consumables including Environmental Monitoring cassettes (TSA-based), Bioburden cassettes (R2A, SDA, TSA), and Rapid Sterility Media. Service offerings include Validation Services, Support Services, and Application Services (feasibility studies and method development). The platform addresses four key QC testing applications: environmental monitoring, water testing, bioburden testing, and sterility testing, serving pharmaceutical, biotechnology, medical device, and personal care product manufacturers.

Product and service9 records
1Growth Direct System
CategoryAutomated Microbial Detection Instrumentation
Description

Flagship automated rapid microbial detection platform that fully automates traditional compendial QC microbiology testing for environmental monitoring, bioburden testing, water testing, and rapid sterility testing. Targeted at pharmaceutical and biotechnology manufacturer QC labs.

2Growth Direct Rapid Sterility System
CategoryRapid Sterility Testing Instrumentation
Description

Fully automated, non-destructive rapid sterility testing platform delivering time-to-detect in as little as 12 hours and final results in 1-3 days, processing up to 126 samples at once with closed-loop design to prevent contamination. For pharmaceutical QC sterility testing.

3Environmental Monitoring Consumable Cassettes
CategoryMicrobiology Consumables
Description

Proprietary media-filled cassettes for environmental monitoring including TSA with Lecithin (ET80) and TSA with LP80HT, produced in controlled cleanroom environments and irradiated for high quality. For use with the Growth Direct System.

4Bioburden and Water Testing Consumable Cassettes
CategoryMicrobiology Consumables
Description

Media cassettes for bioburden and water testing including R2A agar for water testing, Sabouraud Dextrose Agar (SDA) for yeasts and molds, and Tryptic Soy Agar (TSA) for general product testing, available in 48 cassettes per case.

5RMBNucleus Software
CategoryQC Microbiology Software
Description

Next-generation software platform for the Growth Direct System providing secure Windows 10 and SQL Server 2019 support, upgraded reporting and auditing compliant with 21 CFR Part 11, and streamlined recovery, monitoring, and user operation across multiple instruments.

6RMBNucleus Mold Alarm
CategoryQC Microbiology Software
Description

Automated mold detection software feature that triggers alerts when molds are detected during early stages of incubation, enabling investigations to begin in as little as one day and detecting molds commonly causing microbial contamination at temperatures up to 28°C.

7Validation Services
CategoryProfessional Services
Description

Expert validation support partnering with pharmaceutical manufacturers for system qualification, including Installation Qualification (IQ), Operational Qualification (OQ), Performance Qualification (PQ), 21 CFR Part 11 Assessment, Method Qualification/Method Suitability (MQ/MS), and bi-directional LIMS integration, typically completed in four months.

8Support Services
CategoryProfessional Services
Description

Comprehensive support including advanced remote monitoring, preventive maintenance, network connectivity for offsite operation, email alerts for Out Of Specification results and system issues, and an 18-hour-per-day support line.

9Application Services
CategoryProfessional Services
Description

Feasibility studies and method development services performed in Lexington, MA and Freising, Germany laboratories, providing compatibility data, optimized methods, and documentation for Growth Direct System implementation, including product compatibility studies and recovery characteristics assessment.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-03-12
Description

Follow-on multi-system order from Samsung Biologics to expand deployment of Growth Direct platform for automated microbial quality control. The order supports Samsung Biologics' continued expansion of the Growth Direct platform across its contract manufacturing operations, enhancing speed, accuracy, and data integrity in their manufacturing network.

2MilliporeSigma (Merck)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Strategic partnership with MilliporeSigma (Merck) entered its second year with established demo labs. The partnership includes a Services Agreement executed in Q1 2026 to advance strategic collaboration. Expected to drive growth and improve gross margins starting in 2026. The company co-hosts Growth Direct Days events at Merck Innovation Center in Darmstadt, Germany.

stocktitan.net
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Record multi-system rollout from Amgen spanning North America, Europe, and Asia. This represents one of the largest deployments of the Growth Direct System with a top global pharmaceutical company, demonstrating regulatory acceptance and large-scale implementation capability.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global leader in industrial and clinical microbiology, including automated microbial detection and identification platforms. Directly competes with Rapid Micro Biosystems in pharmaceutical QC microbial testing, particularly bioburden, sterility, and environmental monitoring workflows.

TypeDirect peer
Description

Diversifies life sciences and diagnostics with the BD MAX and BD Phoenix M50 systems for microbial identification and detection, plus a broad consumables portfolio. Directly comparable in pharma QC microbiology automation and recurring consumables.

TypeBroad incumbent
Description

Operates a dedicated Microbiology Division offering culture media, identification, and detection systems used in pharma QC labs. RMB's CEO Robert Spignesi was previously VP/GM of Thermo Fisher's Microbiology Division, and Thermo is a broad incumbent with overlapping capabilities in lab analytical instruments.

TypeEmerging player
Description

Supplies bioprocess and QC lab solutions to biopharma manufacturers, including microbial enumeration and contamination control offerings. Overlaps with RMB in biopharma QC lab automation, but is more anchored in upstream/downstream bioprocessing equipment.

TypeBroad incumbent
Description

Major CRO/biopharma services provider that also runs QC microbiology testing and offers endotoxin/microbial detection products. Comparable as an incumbent operating across both lab services and consumables in pharmaceutical QC, including sterility and bioburden testing.

6Beckman Coulter (Danaher)
TypeBroad incumbent
Description

Manufactures a wide range of clinical and life-science lab instruments, including microbiology automation, under Danaher's diagnostics platform. Comparable as a broad incumbent in laboratory analytical instruments with adjacency to pharma QC workflows.

TypeEmerging player
Description

Specializes in automated liquid handling and lab robotics used in QC microbiology, genomics, and pharmaceutical workflows. Comparable as a provider of robotic lab automation that intersects with RMB's Growth Direct robotic imaging and plate handling.

TypeOthers
Description

A leading global CDMO that is also a named RMB customer (Lonza deployed Growth Direct across its global network for end-to-end digital EM). Serves as a buyer and channel reference rather than a direct competitor, but their QC lab buying decisions shape demand for RMB's platform.

9Merck KGaA / MilliporeSigma
TypeOthers
Description

RMB's strategic distribution and demo-lab partner, with an existing Services Agreement to advance the collaboration. Offers competing microbiology QC products but is more directly relevant as the partner driving RMB's channel-led growth and co-hosted 'Growth Direct Days' events.

10Mettler-Toledo International
TypeOthers
Description

Manufactures precision laboratory instruments and process analytics used in pharmaceutical QC environments. Adjacent to RMB in lab analytical instrumentation serving regulated pharma manufacturing, though focused more on weighing, pH, and process analytics than microbial detection.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rapid Micro Biosystems

Automated Microbial Quality Control Instrumentationrapidmicrobio.com

Rapid Micro Biosystems (Nasdaq: RPID) sells the Growth Direct automated rapid microbial detection platform and proprietary consumables to pharmaceutical and biotechnology manufacturers, replacing manual QC microbiology in environmental monitoring, bioburden, water, and sterility testing. The platform serves 75% of the top 20 global pharma companies and generates revenue from system placements plus recurring consumables and software.

What Rapid Micro Biosystems does

Rapid Micro Biosystems (Nasdaq: RPID) is a Lexington, Massachusetts-based life sciences technology company that develops and sells the Growth Direct System, an automated rapid microbial detection platform for quality control microbiology in pharmaceutical and biotechnology manufacturing. The system combines LED-induced autofluorescence imaging with proprietary software algorithms to incubate, image, and count microbial colonies non-destructively, replacing manual plate-handling workflows for environmental monitoring, water testing, bioburden testing, and rapid sterility testing. Proprietary consumables — including media cassettes for TSA, R2A, and SDA formulations produced in cleanroom environments in Lowell, MA — generate recurring revenue tied to the installed base, while the RMBNucleus software platform (with Mold Alarm feature) provides instrument management, compliance reporting under 21 CFR Part 11, and bidirectional LIMS/MES integration.

The company operates a hybrid razor-and-blade business model: capital equipment placements of the Growth Direct system, complemented by high-margin recurring consumables, software subscriptions, and validation/support services. Sales are driven by an enterprise field-sales motion targeting pharmaceutical, biologics, sterile injectable, ATMP, and medical-device manufacturers, augmented by a strategic co-distribution partnership with MilliporeSigma (Merck KGaA) that entered its second year with a Q1 2026 Services Agreement. As of year-end 2025, the platform is used by 75% of the top 20 global pharmaceutical companies including Amgen, Biogen, Lonza, and Samsung Biologics.

FY2025 revenue was approximately $34M (up ~20% YoY), with Q4 2025 setting a record at $11.3M (+37% YoY) driven by a 16-system global rollout with Amgen. FY2026 guidance is $37-41M on expected 30-38 system placements. The company raised $45M in growth capital from Trinity Capital in September 2025 and completed an additional ~$9.8M underwritten offering in May 2026 (with up to ~$32M potential if warrants exercise), anchored by Bain Capital Life Sciences and Armistice Capital. Gross margins have lagged (trailing twelve months around 3%) due to under-absorbed manufacturing, but management is targeting mid-20% gross margins by year-end 2026 as production scales.

Rapid Micro Biosystems firmographics

Firmographics
Name
Rapid Micro Biosystems
Legal name
Rapid Micro Biosystems, Inc.
Website
https://rapidmicrobio.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
101–250 employees
Short description
Rapid Micro Biosystems (Nasdaq: RPID) sells the Growth Direct automated rapid microbial detection platform and proprietary consumables to pharmaceutical and biotechnology manufacturers, replacing manual QC microbiology in environmental monitoring, bioburden, water, and sterility testing. The platform serves 75% of the top 20 global pharma companies and generates revenue from system placements plus recurring consumables and software.
Ownership category
akta.pro rank

Rapid Micro Biosystems industry classification

Industry
Product category
Automated Microbial Quality Control Instrumentation
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)

Keywords

  • Automated microbial detection
  • Pharmaceutical quality control
  • Rapid sterility testing
  • Environmental monitoring systems
  • Bioburden testing instruments

Where Rapid Micro Biosystems is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Rapid Micro Biosystems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain

Revenue model

  1. Capital Equipment Sales: Sale of Growth Direct systems (capital equipment) to pharmaceutical and biotechnology manufacturers for automated microbial quality control testing. The company places systems through direct enterprise sales and strategic partnerships.
  2. Consumables and Test Kits: Recurring revenue from proprietary test consumables including environmental monitoring cassettes, bioburden cassettes, and sterility testing media. Stifel noted consumables growth exceeding 30% driven by expansion of the installed base.
  3. Software and Services: Recurring revenue from software licensing (RMBNucleus platform), support services, validation services, and application services. The company announced plans for cloud-native software platform launch in H2 2026.
  4. Validation and Support Services: Professional services including installation qualification, operational qualification, performance qualification, method qualification, and training. These services support customer implementation and ongoing system maintenance.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Rapid Micro Biosystems product offering

Product offering

Core offering

Rapid Micro Biosystems manufactures and sells the Growth Direct System, an automated rapid microbial detection platform that replaces slow, manual compendial quality control microbiology testing in pharmaceutical and biotechnology manufacturing. The platform combines proprietary autofluorescence imaging hardware, robotic plate handling, RMBNucleus data-management software, and single-use media cassettes to perform environmental monitoring, water testing, bioburden testing, and rapid sterility testing. Revenue is generated from capital equipment sales, recurring consumable cassettes, software licensing, and validation/support services.

Product overview

Rapid Micro Biosystems offers a unified platform architecture centered on the Growth Direct System, an automated rapid microbial detection platform that replaces slow, error-prone manual QC microbiology processes. The product portfolio includes the Growth Direct System hardware and software ecosystem, comprising RMBNucleus software (including the Mold Alarm feature) for instrument control, data management, and automated alerts. The platform is complemented by proprietary consumables including Environmental Monitoring cassettes (TSA-based), Bioburden cassettes (R2A, SDA, TSA), and Rapid Sterility Media. Service offerings include Validation Services, Support Services, and Application Services (feasibility studies and method development). The platform addresses four key QC testing applications: environmental monitoring, water testing, bioburden testing, and sterility testing, serving pharmaceutical, biotechnology, medical device, and personal care product manufacturers.

Differentiator

Problem solved

Functional benefit

Brands

  • Growth Direct®: Flagship automated rapid microbial detection platform for pharmaceutical QC microbiology testing including environmental monitoring, water testing, bioburden testing, and sterility testing.
  • RMBNucleus™
  • RMBNucleus™ Mold Alarm

Products and services

  • Growth Direct System Flagship automated rapid microbial detection platform that fully automates traditional compendial QC microbiology testing for environmental monitoring, bioburden testing, water testing, and rapid sterility testing. Targeted at pharmaceutical and biotechnology manufacturer QC labs.
  • Growth Direct Rapid Sterility System Fully automated, non-destructive rapid sterility testing platform delivering time-to-detect in as little as 12 hours and final results in 1-3 days, processing up to 126 samples at once with closed-loop design to prevent contamination. For pharmaceutical QC sterility testing.
  • Environmental Monitoring Consumable Cassettes Proprietary media-filled cassettes for environmental monitoring including TSA with Lecithin (ET80) and TSA with LP80HT, produced in controlled cleanroom environments and irradiated for high quality. For use with the Growth Direct System.
  • Bioburden and Water Testing Consumable Cassettes Media cassettes for bioburden and water testing including R2A agar for water testing, Sabouraud Dextrose Agar (SDA) for yeasts and molds, and Tryptic Soy Agar (TSA) for general product testing, available in 48 cassettes per case.
  • RMBNucleus Software Next-generation software platform for the Growth Direct System providing secure Windows 10 and SQL Server 2019 support, upgraded reporting and auditing compliant with 21 CFR Part 11, and streamlined recovery, monitoring, and user operation across multiple instruments.
  • RMBNucleus Mold Alarm Automated mold detection software feature that triggers alerts when molds are detected during early stages of incubation, enabling investigations to begin in as little as one day and detecting molds commonly causing microbial contamination at temperatures up to 28°C.
  • Validation Services Expert validation support partnering with pharmaceutical manufacturers for system qualification, including Installation Qualification (IQ), Operational Qualification (OQ), Performance Qualification (PQ), 21 CFR Part 11 Assessment, Method Qualification/Method Suitability (MQ/MS), and bi-directional LIMS integration, typically completed in four months.
  • Support Services Comprehensive support including advanced remote monitoring, preventive maintenance, network connectivity for offsite operation, email alerts for Out Of Specification results and system issues, and an 18-hour-per-day support line.
  • Application Services Feasibility studies and method development services performed in Lexington, MA and Freising, Germany laboratories, providing compatibility data, optimized methods, and documentation for Growth Direct System implementation, including product compatibility studies and recovery characteristics assessment.

Quantifiable outcome

  • Time savings of up to 60% in bioburden detection (Biogen case study)
  • +7 more outcomes

Companies that use Rapid Micro Biosystems

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Rapid Micro Biosystems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature7 records

Rapid Micro Biosystems partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered major and core.

  • Samsung BiologicsmajorStrategic or Co-development Partner · 12 March 2026Follow-on multi-system order from Samsung Biologics to expand deployment of Growth Direct platform for automated microbial quality control. The order supports Samsung Biologics' continued expansion of the Growth Direct platform across its contract manufacturing operations, enhancing speed, accuracy, and data integrity in their manufacturing network.
  • MilliporeSigma (Merck)coreStrategic or Co-development Partner · 1 January 2026Strategic partnership with MilliporeSigma (Merck) entered its second year with established demo labs. The partnership includes a Services Agreement executed in Q1 2026 to advance strategic collaboration. Expected to drive growth and improve gross margins starting in 2026. The company co-hosts Growth Direct Days events at Merck Innovation Center in Darmstadt, Germany.
  • AmgenmajorStrategic or Co-development PartnerRecord multi-system rollout from Amgen spanning North America, Europe, and Asia. This represents one of the largest deployments of the Growth Direct System with a top global pharmaceutical company, demonstrating regulatory acceptance and large-scale implementation capability.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Rapid Micro Biosystems competitors and assessment

Company assessment

Direct peers

  • bioMérieux: Global leader in industrial and clinical microbiology, including automated microbial detection and identification platforms. Directly competes with Rapid Micro Biosystems in pharmaceutical QC microbial testing, particularly bioburden, sterility, and environmental monitoring workflows.
  • Becton, Dickinson and Company (BD): Diversifies life sciences and diagnostics with the BD MAX and BD Phoenix M50 systems for microbial identification and detection, plus a broad consumables portfolio. Directly comparable in pharma QC microbiology automation and recurring consumables.

Broad incumbents

  • Thermo Fisher Scientific: Operates a dedicated Microbiology Division offering culture media, identification, and detection systems used in pharma QC labs. RMB's CEO Robert Spignesi was previously VP/GM of Thermo Fisher's Microbiology Division, and Thermo is a broad incumbent with overlapping capabilities in lab analytical instruments.
  • Charles River Laboratories: Major CRO/biopharma services provider that also runs QC microbiology testing and offers endotoxin/microbial detection products. Comparable as an incumbent operating across both lab services and consumables in pharmaceutical QC, including sterility and bioburden testing.
  • Beckman Coulter (Danaher): Manufactures a wide range of clinical and life-science lab instruments, including microbiology automation, under Danaher's diagnostics platform. Comparable as a broad incumbent in laboratory analytical instruments with adjacency to pharma QC workflows.

Emerging players

  • Sartorius AG: Supplies bioprocess and QC lab solutions to biopharma manufacturers, including microbial enumeration and contamination control offerings. Overlaps with RMB in biopharma QC lab automation, but is more anchored in upstream/downstream bioprocessing equipment.
  • Hamilton Company: Specializes in automated liquid handling and lab robotics used in QC microbiology, genomics, and pharmaceutical workflows. Comparable as a provider of robotic lab automation that intersects with RMB's Growth Direct robotic imaging and plate handling.

Others

  • Lonza Group: A leading global CDMO that is also a named RMB customer (Lonza deployed Growth Direct across its global network for end-to-end digital EM). Serves as a buyer and channel reference rather than a direct competitor, but their QC lab buying decisions shape demand for RMB's platform.
  • Merck KGaA / MilliporeSigma: RMB's strategic distribution and demo-lab partner, with an existing Services Agreement to advance the collaboration. Offers competing microbiology QC products but is more directly relevant as the partner driving RMB's channel-led growth and co-hosted 'Growth Direct Days' events.
  • Mettler-Toledo International: Manufactures precision laboratory instruments and process analytics used in pharmaceutical QC environments. Adjacent to RMB in lab analytical instrumentation serving regulated pharma manufacturing, though focused more on weighing, pH, and process analytics than microbial detection.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Rapid Micro Biosystems social profiles

Digital presence

Rapid Micro Biosystems compliance and trust

Trust signal

Compliance7 records

Rapid Micro Biosystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rapid Micro Biosystems leadership team

Management profile

Number of profiles

Profiles9 records

Rapid Micro Biosystems funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rapid Micro Biosystems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rapid Micro Biosystems

What does Rapid Micro Biosystems do?

Rapid Micro Biosystems manufactures and sells the Growth Direct System, an automated rapid microbial detection platform that replaces slow, manual compendial quality control microbiology testing in pharmaceutical and biotechnology manufacturing. The platform combines proprietary autofluorescence imaging hardware, robotic plate handling, RMBNucleus data-management software, and single-use media cassettes to perform environmental monitoring, water testing, bioburden testing, and rapid sterility testing. Revenue is generated from capital equipment sales, recurring consumable cassettes, software licensing, and validation/support services.

Is Rapid Micro Biosystems a public or private company?

Rapid Micro Biosystems is a public company. It is classified as public and is currently operating.

When was Rapid Micro Biosystems founded?

Rapid Micro Biosystems was founded in 2006. It employs 101 to 250 people.

Where is Rapid Micro Biosystems based?

Rapid Micro Biosystems is headquartered in Lexington, United States, in the North America region.

How does Rapid Micro Biosystems make money?

Four revenue lines are on record. Capital Equipment Sales are the primary driver. The others are consumables and Test Kits, software and Services and validation and Support Services.

Who are Rapid Micro Biosystems's main competitors?

Direct peers on record are bioMérieux and Becton, Dickinson and Company (BD). Broad incumbents are Thermo Fisher Scientific, Charles River Laboratories and Beckman Coulter (Danaher). Emerging players are Sartorius AG and Hamilton Company. Others are Lonza Group, Merck KGaA / MilliporeSigma and Mettler-Toledo International.

Does Rapid Micro Biosystems have an API?

No public API is recorded for Rapid Micro Biosystems.

What industry is Rapid Micro Biosystems in?

Rapid Micro Biosystems's product category is Automated Microbial Quality Control Instrumentation. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Rapid Micro Biosystems, Inc. (NASDAQ: RPID)Monteverde & Associates PC announced an investigation of Rapid Micro Biosystems' proposed sale to Merck KGaA. Under the deal, Rapid Micro shareholders would receive $0.75 in cash per share. The firm invites shareholders to contact the firm for more information.PR NewswireAre GLND, RPID, AYTU Obtaining Fair Deals for their Shareholders?Halper Sadeh LLC is investigating Greenland Energy, Rapid Micro Biosystems, and Aytu BioPharma for potential securities law violations and fiduciary breaches. Greenland shareholders would own about 50% of the combined company after its merger with 80 Mile plc, while Rapid and Aytu are being sold to Merck and Rosemont at $0.75 and $2.70 per share, respectively.FinancialContent Business PageBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Aytu BioPharma, Inc. (Nasdaq – AYTU), Rapid Micro Biosystems, Inc. (Nasdaq – RPID), Advantage Energy Ltd. (OTCBrodsky & Smith notified investors of four shareholder investigations into merger transactions. The cases involve Aytu BioPharma, Rapid Micro Biosystems, Advantage Energy, and Canaccord Genuity, each with specific acquisition prices and fiduciary duty questions. No cost or financial obligation is stated for investors.GlobeNewswireBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Aytu BioPharma, Inc. (Nasdaq – AYTU), Rapid Micro Biosystems, Inc. (Nasdaq – RPID), Advantage Energy Ltd. (OTC – AAVVF), Canaccord Genuity Group Inc. (OTC – CCORF)Brodsky & Smith notified investors of investigations into four companies: Aytu BioPharma, Rapid Micro Biosystems, Advantage Energy, and Canaccord Genuity. The investigations question whether each company's board breached fiduciary duties by failing to conduct a fair process in their respective mergers, including whether the transactions pay fair value to shareholders.Investing.comRoth/MKM cuts Rapid Micro Biosystems stock rating on Merck dealRoth/MKM downgraded Rapid Micro Biosystems to Neutral and cut its price target to $0.75 from $3.00 after the company agreed to be acquired by Merck for $0.75 per share in cash. The deal is expected to close in December 2026, and the acquisition price is a slight discount to InvestingPro's fair value of $0.94.FinancialContent Business PageRPID Stock Alert: Halper Sadeh LLC is Investigating Whether Rapid Micro Biosystems, Inc. is Obtaining a Fair Price for its ShareholdersHalper Sadeh LLC is investigating Rapid Micro Biosystems' proposed $0.75-per-share sale to Merck KGaA, alleging potential securities law violations and fiduciary breaches. The firm may seek increased consideration, additional disclosures, or other relief on a contingent fee basis.FinancialContent Business PageRPID Shareholder Alert: ADEMI LLP Investigates Whether Buyout Fairly Values Rapid Micro Biosystems, Inc.Ademi LLP is investigating the proposed Merck acquisition of Rapid Micro Biosystems, focusing on whether the deal price fairly values the company and whether insiders received substantial change-of-control benefits. The firm also examines restrictions on competing offers and the board's conduct. Shareholders are invited to contact the firm for more information.GlobeNewswireRPID Shareholder Alert: ADEMI LLP Investigates Whether Buyout Fairly Values Rapid Micro Biosystems, Inc.Ademi LLP is investigating the proposed Merck acquisition of Rapid Micro Biosystems, focusing on whether the deal provides fair value to public shareholders. The investigation covers the purchase price, insider benefits, and restrictions on competing offers, including a significant termination penalty.